natgillin/translations-raw huggingface dataset:
In the virologic failures of the ARTEMIS trial no cross-resistance with other PIs was observed. 
Kod viroloških neuspjeha u kliničkom ispitivanju ARTEMIS nije uočena križna rezistencija s drugim IP.
Interactions between darunavir/ritonavir and antiretroviral and non-antiretroviral medicinal products are listed in the table below. 
Interakcije između darunavira/ritonavira i antiretrovirusnih te ne-antiretrovirusnih lijekova navedene su u donjoj tablici.
Due to uncertainties regarding the rate of development of the human blood brain barrier and liver enzymes, darunavir with low dose ritonavir should not be used in paediatric patients below 3 years of age. 
S obzirom na nesigurnost vezanu uz poznavanje brzine razvoja ljudske krvnomoždane barijere i jetrenih enzima, darunavir s niskom dozom ritonavira ne smije se primjenjivati pedijatrijskim bolesnicima mlađima od 3 godine starosti.
common angioedema, pruritus, urticaria rare drug reaction with eosinophilia and systemic symptoms*, Stevens-Johnson syndrome* 
često angioedem, pruritus, urtikarija rijetko reakcija na lijek s eozinofilijom i sistemskim simptomima*, Stevens-Johnsonov sndrom*
(CYP3A inhibition) 
(CYP3A inhibicija)
HMG CO-A REDUCTASE INHIBITORS Lovastatin 
INHIBITORI HMG CO-A REDUKTAZE Lovastatin
No human data on the effect of darunavir on fertility are available. 
Nema dostupnih podataka o učinku darunavira na plodnost u ljudi.
It is therefore important to talk to your doctor if you develop a rash. 
Stoga je važno da razgovarate s liječnikom ako se pojavi osip.
After 2 years administration of darunavir at exposures at or below the human exposure, kidney changes were observed in mice (nephrosis) and rats (chronic progressive nephropathy). 
Nakon 2 godine primjene darunavira pri izloženostima koja je jednaka ili ispod izloženosti u ljudi, primijećene su promjene na bubrezima u miševa (nefroza) i štakora (kronična progresivna nefropatija).
The effects of high fluticasone systemic exposure on ritonavir plasma levels are unknown. 
Učinci visoke sistemske izloženosti flutikazona na razine ritonavira u plazmi nisu poznati.
You must take Darunavir Krka every day and always in combination with 100 milligram of ritonavir and with food. 
Lijek Darunavir Krka morate uzimati svaki dan i uvijek u kombinaciji sa 100 miligrama ritonavira i s hranom.
Several of the interaction studies have been performed with darunavir at lower than recommended doses. 
Provedeno je nekoliko ispitivanja interakcija s darunavirom u dozama nižima od preporučenih.
At the highest tested doses, the systemic exposures (based on AUC) to darunavir were between 0.4- and 0.7-fold (mice) and 0.7- and 1-fold (rats), relative to those observed in humans at the recommended therapeutic doses. 
Pri najvišim ispitivanim dozama, sistemske izloženosti darunaviru (temeljene na AUC), bila je veća između 0,4 i 0,7 puta (u miševa) te 0,7 i 1 puta (u štakora), u odnosu na opaženu izloženost u ljudi pri preporučenom terapijskim dozama.
Increasing baseline darunavir fold change in EC50 (FC) was associated with decreasing virologic response. 
Povišenje početne promjene vrijednosti (PV) EC50 darunavira bilo je povezano sa smanjenim virološkim odgovorom.
Changes were observed in liver (hepatocyte hypertrophy, vacuolation, increased liver enzymes) and thyroid (follicular hypertrophy). 
Primjećene su promjene na jetri (hipertrofija hepatocita, vakuolizacija, povišeni enzimi jetre) i štitnjači (hipertrofija folikula).
Darunavir/ritonavir may be considered as an alternative. 
Darunavir/ritonavir mogu se uzeti u obzir kao zamjena.
Darunavir/ritonavir should not be used in children with a body weight of less than 15 kg as the dose for this population has not been established in a sufficient number of patients (see section 5.1). 
Darunavir /ritonavir se ne smije primjenjivati u djece s tjelesnom težinom manjom od 15 kg, jer doza za ovu populaciju nije ustanovljena na dovoljnom broju bolesnika (vidjeti dio 5.1).
Limited information is available in this population, and therefore, darunavir should be used with caution in this age group (see sections 4.4 and 5.2). 
Za ovu populaciju dostupne su ograničene informacije, stoga se darunavir u toj dobnoj skupini mora primjenjivati s oprezom (vidjeti dijelove 4.4 i 5.2).
║ based on published data with darunavir/ritonavir rosuvastatin AUC ↑ 93% rosuvastatin Cmax ↑ 277% rosuvastatin Cmin ND 
║ na temelju objavljenih podataka s darunavirom/ritonavirom rosuvastatin AUC ↑ 93% rosuvastatin Cmax ↑ 277% rosuvastatin Cmin NO
ANTINEOPLASTICS Dasatinib 
ANTINEOPLASTICI Dasatinib
These results were confirmed in the analyses of data at 96 weeks of treatment in the ARTEMIS trial. 
Ti su rezultati potvrđeni analizom podataka u 96. tjednu liječenja u ispitivanju ARTEMIS.
People taking Darunavir Krka may develop a skin rash. 
Osobe koje uzimaju Darunavir Krka mogu razviti kožni osip.
Darunavir FC was less than 10 for 90% of 3,309 clinical isolates resistant to amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and/or tipranavir showing that viruses resistant to most PIs remain susceptible to darunavir. 
PV darunavira bila je manja od 10 puta za 90% od 3309 kliničkih izolata rezistentnih na amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, sakvinavir i/ili tipranavir pokazujući da virusi rezistentni na većinu IP-a ostaju osjetljivi na darunavir.
20 mg once daily 
20 mg jedanput na dan
Single doses up to 3,200 mg of darunavir as oral solution alone and up to 1,600 mg of the tablet formulation of darunavir in combination with ritonavir have been administered to healthy volunteers without untoward symptomatic effects. 
Jednokratne doze do 3200 mg darunavira u obliku oralne otopine same i do 1600 mg darunavira u obliku tableta u kombinaciji s ritonavirom primjenjivale su se zdravim dobrovoljcima bez neželjenih simptomatskih učinaka.
Elimination After a 400/100 mg 
Nakon doze od 400/100 mg
Fluticasone: in a clinical study where ritonavir 100 mg capsules twice daily were co-administered with 50 μg intranasal fluticasone propionate (4 times daily) for 7 days in healthy subjects, fluticasone propionate plasma concentrations increased significantly, whereas the intrinsic cortisol levels decreased by approximately 86% (90% CI 82-89%). 
Flutikazon: u kliničkom ispitivanju gdje su ritonavir 100 mg kapsule dvaput na dan istodobno primijenjene s 50 μg intranazalnog flutikazon propionata (4 puta na dan) tijekom 7 dana u zdravih ispitanika, značajno su porasle koncentracije flutikazon propionata u plazmi, dok su se razine intrinzičnog kortizola snizile približno 86% (90% CI 82-89%).
For the treatment of pulmonary arterial hypertension Sildenafil 
Za liječenje plućne arterijske hipertenzije
The combination may result in increased risk of cardiovascular adverse event with salmeterol, including QT prolongation, palpitations and sinus tachycardia. 
Kombinacija može rezultirati povećanim rizikom od kardiovaskularnog štetnog događaja sa salmeterolom, uključujući produljenje QT intervala, palpitacije i sinusnu tahikardiju.
Based on pharmacokinetic modeling, this dosage reduction of 75% is also applicable if patients receive rifabutin at doses other than 300 mg/day. 
Na osnovu farmakokinetičkog modela, ovo sniženje doze od 75% primjenjivo je također ako bolesnici primaju rifabutin pri dozama različitim od 300 mg/dan.
The safety and efficacy of darunavir have not been established in patients with severe underlying liver disorders and darunavir is therefore contraindicated in patients with severe hepatic impairment. 
Sigurnost i djelotvornost darunavira nije ustanovljena u bolesnika s teškim podležećim poremećajima jetre, stoga je darunavir kontraindiciran u bolesnika s teškim oštećenjem funkcije jetre.
Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after boosted darunavir given with food. 
Didanozin treba primijeniti na prazan želudac, odnosno treba ga primijeniti 1 sat prije ili 2 sata nakon pojačanog darunavira koji se uzima s hranom.
* these adverse drug reactions have not been reported in clinical trial experience with darunavir/cobicistat but have been noted with darunavir/ritonavir treatment and could be expected with darunavir/cobicistat too. 
* ove nuspojave nisu prijavljene tijekom iskustva iz kliničkih ispitivanja s darunavirom/kobicistatom ali su zabilježene tijekom liječenja s darunavirom/ritonavirom, te se također mogu očekivati s darunavirom/kobicistatom.
Otherwise, there were no effects on mating or fertility with darunavir treatment up to 1,000 mg/kg/day and exposure levels below (AUC-0.5 fold) of that in human at the clinically recommended dose. 
S druge strane, nije bilo učinka na parenje ili plodnost s liječenjem darunavirom do 1000 mg/kg/dan i razina izloženosti ispod onih (AUC - 0,5 puta) klinički preporučenih doza za ljude.
The absolute oral bioavailability of a single 600 mg dose of darunavir alone was approximately 37% and increased to approximately 82% in the presence of 100 mg twice daily ritonavir. 
Apsolutna peroralna bioraspoloživost jednokratne doze od 600 mg samog darunavira bila je približno 37% i porasla na približno 82% u prisutnosti ritonavira od 100 mg dvaput na dan.
However, adjustment of the methadone dose may be necessary when concomitantly administered for a longer period of time. 
Međutim, prilagodba doze metadona možda će biti potrebna kada se istodobno primjenjuju tijekom duljeg vremena.
Drug-induced hepatitis (e.g. acute hepatitis, cytolytic hepatitis) has been reported with darunavir. 
Lijekom izazvan hepatitis (npr. akutni hepatitis, citolitički hepatitis) bio je prijavljen kod liječenja darunavirom.
Tablet dimension: 20 x 10 mm. 
Dimenzija tablete: 20 x 10 mm.
Strong CYP3A inducers include e.g. carbamazepine, phenobarbital and phenytoin (see sections 4.4 and 4.5). 
Snažni induktori CYP3A uključuju npr. karbamazepin, fenobarbital i fenitoin (vidjeti dijelove 4.4 i 4.5).
Renal impairment Results from a mass balance study with 
Rezultati ispitivanja masene ravnoteže s
Sertraline 50 mg once daily 
Sertralin 50 mg jedanput na dan
Following intravenous administration, the volume of distribution of darunavir alone was 88.1 ± 59.0 l (Mean ± SD) and increased to 131 ± 49.9 l (Mean ± SD) in the presence of 100 mg twice-daily ritonavir. 
Nakon intravenske primjene, volumen distribucije samog darunavira bio je 88,1 ± 59,0 l (srednja vrijednost ± SD) i povećao se na 131 ± 49,91 (srednja vrijednost ± SD) u prisutnosti 100 mg ritonavira dvaput na dan.
Co-administration with strong CYP3A4 inhibitors is not recommended and caution is warranted, these interactions are described in the interaction table below (e.g. indinavir, azole antifungals like clotrimazole). 
Istodobna primjena sa snažnim CYP3A4 inhibitorima se ne preporučuje i savjetuje se oprez, ove interakcije opisane su u tablici interakcija ispod (npr. indinavir, antifungalni azoli poput klotrimazola).
Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to combination antiretroviral therapy (CART). 
Iako se smatra da je etiologija višeznačna (uključuje primjenu kortikosteroida, konzumaciju alkohola, tešku imunosupresiju, viši indeks tjelesne mase), slučajevi osteonekroze prijavljeni su naročito u bolesnika s uznapredovalom HIV bolešću i/ili s dugotrajnom izloženošću kombiniranoj antiretrovirusnoj terapiji (KART).
CALCIUM CHANNEL BLOCKERS Amlodipine 
BLOKATORI KALCIJEVIH KANALA Amlodipin
The recommendations given for concomitant use of darunavir and other medicinal products may therefore differ depending on whether darunavir is boosted with ritonavir or cobicistat (see sections 4.3 and 4.4), and caution is also required during the first time of treatment if switching the pharmacoenhancer from ritonavir to cobicistat (see section 4.4). 
Preporuke za istodobnu primjenu darunavira i drugih lijekova mogu se stoga razlikovati, ovisno o tome je li darunavir pojačan ritonavirom ili kobicistatom (vidjeti dijelove 4.3 i 4.4), a oprez je također potreban tijekom prvog liječenja ako se mijenja farmakokinetički pojačivač s ritonavira na kobicistat (vidjeti dio 4.4).
What you need to know before you take Darunavir Krka 
Što morate znati prije nego počnete uzimati Darunavir Krka
Other tablet strengths and formulations of darunavir are available. 
Dostupne su druge jačine tableta i oblici darunavira.
Based upon the safety profile of darunavir/ritonavir, the increase in darunavir exposure in the presence of rifabutin does not warrant a dose adjustment for darunavir/ritonavir. 
Na temelju sigurnosnog profila darunavira/ritonavira, povišena izloženost darunaviru u prisustvu rifabutina ne zahtjeva prilagodbu doze darunavira/ritonavira.
The intravenous clearance of darunavir alone (150 mg) and in the presence of low dose ritonavir was 32.8 l/h and 5.9 l/h, respectively. 
Intravenski klirens samog darunavira (150 mg) i u prisutnosti niske doze ritonavira bio je 32,8 l/h, odnosno 5,9 l/h.
Midazolam(oral) Triazolam 
Midazolam (peroralni) Triazolam
Limited data are available in patients with HIV-1 clades other than B (see section 5.1). 
Za bolesnike s drugim podtipovima HIV-1 osim B dostupni su ograničeni podaci (vidjeti dio 5.1).
The recommended dose of darunavir with low dose ritonavir for paediatric patients is based on body weight and should not exceed the recommended adult dose (600/100 mg twice daily or 800/100 mg once daily). 
Preporučena doza darunavira s niskom dozom ritonavira za pedijatrijske bolesnike temelji se na tjelesnoj težini i ne smije prelaziti preporučenu dozu za odrasle (600/100 mg dvaput na dan ili 800/100 mg jedanput na dan).
INTERACTIONS AND DOSE RECOMMENDATIONS WITH OTHER MEDICINAL PRODUCTS Medicinal products by therapeutic areas 
INTERAKCIJE I PREPORUČENE DOZE S DRUGIM LIJEKOVIMA
Darunavir Krka has only been used in limited numbers of patients 65 years or older. 
Darunavir Krka je primjenjivan samo u ograničenog broja bolesnika u dobi od 65 godina ili starijih.
Therefore, no special precautions or dose adjustments are required in these patients (see sections 4.2 and 5.2). 
Prema tome, u takvih bolesnika nisu potrebne posebne mjere opreza ili prilagodbe doze (vidjeti dijelove 4.2 i 5.2).
Cobicistat decreases the estimated creatinine clearance due to inhibition of tubular secretion of creatinine. 
Kobicistat snižava procijenjeni klirens kreatinina zbog inhibicije tubularne skerecije kreatinina.
The doctor will inform you on how many Darunavir Krka tablets and how much ritonavir (capsules, tablets or solution) the child must take. 
Liječnik će Vas informirati koliko Darunavir Krka tableta i koliko ritonavira (kapsula, tableta ili otopine) dijete mora uzeti.
However, increased methadone dose may be necessary when concomitantly administered for a longer period of time due to induction of metabolism by ritonavir. 
Međutim, možda će biti potrebno povišenje doze metadona kada se istodobno primjenjuju tijekom duljeg vremena zbog indukcije metabolizma ritonavirom.
After therapy with darunavir has been initiated, patients should be advised not to alter the dosage, dose form or discontinue therapy without discussing with their health care provider. 
Nakon početka terapije darunavirom, bolesnicima se mora savjetovati da ne mijenjaju doziranje, oblik doze niti da prekidaju terapiju, bez da o tome nisu razgovarali s liječnikom.
This protein binding is concentrationdependent indicative for saturation of binding. 
Ovo je vezanje na protein ovisno o koncentraciji i pokazatelj je mogućnosti zasićenja vezanja.
Darunavir exhibits activity against laboratory strains and clinical isolates of HIV-1 and laboratory strains of HIV-2 in acutely infected T-cell lines, human peripheral blood mononuclear cells and human monocytes/macrophages with median EC50 values ranging from 1.2 to 8.5 nM (0.7 to 5.0 ng/ml). 
Darunavir pokazuje aktivnost protiv laboratorijskih sojeva i kliničkih izolata HIV-1 te laboratorijskih sojeva HIV-2 u akutno inficiranim linijama T-stanica, humanim mononuklearnim stanicama iz periferne krvi i humanim monocitima/makrofagima s medijanom vrijednosti EC50 u rasponu od 1,2 do 8,5 nM (0,7 do 5,0 ng/ml).
During attempts to overcome the decreased exposure by increasing the dose of other protease inhibitors with low dose ritonavir, a high frequency of liver reactions was seen with rifampicin. 
Tijekom pokušaja da se prevlada smanjenje izloženosti, povisujući dozu drugih inhibitora proteaze s niskom dozom ritonavira, došlo je do povišene učestalosti jetrenih reakcija s rifampicinom.
Both arms used a fixed background regimen consisting of tenofovir disoproxil fumarate 300 mg once daily and emtricitabine 200 mg once daily. 
U obje skupine primijenjen je točno određeni osnovni režim koji se sastojao od tenofovirdizoproksilfumarata 300 mg jedanput na dan i emtricitabina 200 mg jedanput na dan.
In the rat, the combination of darunavir with ritonavir lead to a small increase in effect on RBC parameters, liver and thyroid and increased incidence of islet fibrosis in the pancreas (in male rats only) compared to treatment with darunavir alone. 
U štakora, kombinacija darunavira s ritonavirom dovela je do malog povećanja učinka na parametre eritrocita, jetru i štitnjaču, te povećane incidencije fibroznih otočića u pankreasu (samo u mužjaka štakora) u usporedbi s liječenjem sa samim darunavirom.
These patients received darunavir/ritonavir 800/100 mg once daily in combination with other antiretroviral agents. 
Ovi bolesnici su primili darunavir/ritonavir 800/100 mg jedanput na dan u kombinaciji s drugim antiretrovirusnim lijekovima.
There were no new clinically relevant safety findings compared with the known safety profile of darunavir/ritonavir in HIV-1 infected adults (see sections 4.2, 4.4 and 5.2). 
Nisu zabilježeni novi klinički značajni sigurnosni podaci u usporedbi s poznatim sigurnosnim profilom darunavira/ritonavira u HIV-1 inficiranih odraslih bolesnika (vidjeti dijelove 4.2, 4.4 i
ANTIANGINA/ANTIARRHYTHMIC 
ANTIANGINICI/ANTIARITMICI
Life-threatening and fatal drug interactions have been reported in patients treated with colchicine and strong inhibitors of CYP3A and P-glycoprotein (P-gp; see sections 4.3 and 4.5). 
Po život opasne i fatalne interakcije lijekova prijavljene su u bolesnika liječenih kolhicinom i snažnim inhibitorima CYP3A i P-glikoproteina (P-gp; vidjeti dijelove 4.3 i 4.5).
Study was conducted with tenofovir disoproxil fumarate 300 mg once daily. 
Ispitivanje je provedeno s tenofovirdizoproksilfumaratom 300 mg jedanput na dan.
There is an increased potential for sildenafil-associated adverse events (including visual disturbances, hypotension, prolonged erection and syncope). 
Povećana je mogućnost od štetnih događaja povezanih sa sildenafilom (uključujući poremećaje vida, hipotenziju, produljenu erekciju i sinkopu).
The table below shows the efficacy data of the 48-week and 96-week analyses from the pooled POWER 1 and POWER 2 trials. 
Tablica ispod prikazuje objedinjene podatke djelotvornosti nakon 48 i 96 tjedana u ispitivanjima POWER 1 i POWER 2.
Disopyramide Flecainide Lidocaine (systemic) Mexiletine Propafenone 
Lidokain (sistemski) Meksiletin Propafenon
ethinylestradiol AUC  30% ethinylestradiol Cmin ND 
etinilestradiol AUC  30% etinilestradiol Cmin NO
PHOSPHODIESTERASE, TYPE 5 (PDE-5) INHIBITORS 
INHIBITORI FOSFODIESTERAZE, TIP 5 (PDE-5)
If switching the pharmacoenhancer from ritonavir to cobicistat, caution is required during the first two weeks of treatment with darunavir/cobicistat, particularly if doses of any concomitantly administered medicinal products have been titrated or adjusted during use of ritonavir as a pharmacoenhancer. 
Ako se mijenja farmakokinetički pojačivač sa ritonavira na kobicistat, potreban je oprez tijekom prva dva tjedna liječenja darunavirom/kobicistatom, naročito ako su doze bilo kojeg od istodobno primijenjenih lijekova titrirane ili prilagođene tijekom primjene ritonavira kao farmakokinetičkog pojačivača.
For co-administration with strong CYP3A4 inhibitors, the same recommendations apply independent of whether darunavir is boosted with ritonavir or with cobicistat (see section above). 
Za istodobnu primjenu sa snažnim CYP3A4 inhibitorima, odnose se iste preporuke, neovisno o tome je li darunavir pojačan s ritonavirom ili kobicistatom (vidjeti dio iznad).
Response (HIV-1 RNA < 50 copies/ml at week 24) %, n/N 
Odgovor (HIV-1 RNK < 50 kopija/ml u 24. tjednu) %, n/N
Given that digoxin has a narrow therapeutic index, it is recommended that the lowest possible dose of digoxin should initially be prescribed in case digoxin is given to patients on boosted darunavir therapy. 
Budući da digoksin ima uzak terapijski indeks, preporučuje se inicijalno propisati najnižu moguću dozu digoksina u slučaju kada se digoksin daje bolesnicima koji su na terapiji pojačanim darunavirom.
ANTINEOPLASTICS 
ANTINEOPLASTICI
R(-) methadone AUC ↓ 16% R(-) methadone Cmin ↓ 15% R(-) methadone Cmax ↓ 24% darunavir /cobicistat may, in contrast, increase methadone plasma concentrations (see cobicistat SmPC). 
R(-) metadon AUC ↓ 16% R(-) metadon Cmin ↓ 15% R(-) metadon Cmax ↓ 24% Nasuprot tome, darunavir/kobicistat može povećati koncentracije metadona u plazmi (vidjeti SmPC za kobicistat).
Patients with severe (Child-Pugh Class C) hepatic impairment. 
Bolesnici s teškim oštećenjem funkcije jetre (Child-Pugh stadij C).
Cobicistat has not been studied in patients receiving dialysis, therefore, no recommendation can be made for the use of darunavir/cobicistat in these patients (see section 4.2). 
Kobicistat nije ispitan u bolesnika na dijalizi, stoga se ne mogu dati preporuke za primjenu darunavira/kobicistata u ovih bolesnika (vidjeti dio 4.2).
A lower and upper clinical cut-off of 10 and 40 were identified. 
Kao kliničke granice identificirani su 10-struko i 40-struko povećanje.
* DRV-RAMs: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V and L89V 
* DRV-RAM: V11I, V32I, L33F, I47V, I50V, I54M, I54L, T74P, L76V, I84V i L89V
Didanosine is to be administered on an empty stomach, thus it should be administered 1 hour before or 2 hours after darunavir/ritonavir given with food. 
Didanozin treba primijeniti na prazan želudac, odnosno treba ga primijeniti 1 sat prije ili 2 sata nakon darunavira/ritonavira koji se uzima s hranom.
Darunavir demonstrates antiviral activity in vitro against a broad panel of HIV-1 group M (A, B, C, D, E, F, G) and group O primary isolates with EC50 values ranging from < 0.1 to 4.3 nM. 
Darunavir pokazuje antivirusnu aktivnost in vitro protiv širokog panela HIV-1 skupine M (A, B, C, D, E, F, G) i skupine O primarno izolata s EC50 vrijednostima u rasponu od < 0,1 do 4,3 nM.
If there is a need to combine darunavir/ritonavir and carbamazepine, patients should be monitored for potential carbamazepine-related adverse events. 
U slučaju potrebe za kombinacijom darunavira/ritonavira i karbamazepina, bolesnike se mora pratiti zbog potencijalnih nuspojava povezanih s karbamazepinom.
Increased plasma concentrations of lovastatin or simvastatin may cause myopathy, including rhabdomyolysis. 
Povišene koncentracije lovastatina ili simvastatina u plazmi mogu uzrokovati miopatiju, uključujući rabdomiolizu.
Tablet dimension: 19.5 x 10 mm. 
Dimenzija tablete: 19,5 x 10 mm.
C-darunavir trial in healthy volunteers showed that a majority of the radioactivity in plasma after a single 400/100 mg darunavir with ritonavir dose was due to the parent active substance. 
Cdarunavir na zdravim dobrovoljcima pokazalo je da većinu radioaktivnosti u plazmi nakon jednostruke doze od 400/100 mg darunavira s ritonavirom treba pripisati osnovnoj djelatnoj tvari.
Darunavir Krka works by reducing the amount of HIV in your body. 
Darunavir Krka djeluje tako da smanjuje količinu virusa HIV-a u Vašem tijelu.
Buspirone 
Buspiron
Some side effects are typical for anti-HIV medicines in the same family as Darunavir Krka. 
Neke su nuspojave tipične za lijekove protiv HIV-a koji spadaju u istu skupinu kao i Darunavir Krka.
Tell your doctor if you have diabetes. 
- Upozorite liječnika ako imate šećernu bolest.